[{"NetIncomeLoss_1_Q2_USD":-11118441.0,"AccruedLiabilitiesCurrent_0_Q2_USD":1360933.0,"InterestPaidNet_2_Q2_USD":954.0,"IncomeTaxesPaid_2_Q2_USD":null,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-39970532.0,"Depreciation_2_Q2_USD":2075.0,"ProceedsFromSaleOfShortTermInvestments_2_Q2_USD":22393644.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":19855018.0,"AssetsCurrent_0_Q2_USD":134404581.0,"OperatingLeaseExpense_2_Q2_USD":83000.0,"AccruedVacationCurrent_0_Q2_USD":232600.0,"ContractualObligationDueInNextTwelveMonths_0_Q2_USD":82800.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":7039944.0,"CommonStockSharesIssued_0_Q2_shares":15851853.0,"UnrealizedLossOnSecurities_2_Q2_USD":287027.0,"Assets_0_Q2_USD":134559451.0,"UnrealizedGainLossOnInvestments_2_Q2_USD":287027.0,"ShareBasedCompensation_2_Q2_USD":12341875.0,"ContractualObligation_0_Q2_USD":82800.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":15323051.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":15030641.0,"GeneralAndAdministrativeExpense_1_Q2_USD":7433249.0,"GeneralAndAdministrativeExpense_2_Q2_USD":12899903.0,"ResearchAndDevelopmentExpense_2_Q2_USD":9831737.0,"ResearchAndDevelopmentExpense_1_Q2_USD":5323953.0,"IncreaseDecreaseInPrepaidExpense_2_Q2_USD":-183329.0,"PrepaidExpenseCurrent_0_Q2_USD":240534.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":535997.0,"CommonStockValue_0_Q2_USD":15852.0,"PrepaidExpenseCurrentAndNoncurrent_0_Q2_USD":240500.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0_Q2_USD":1500000.0,"StockIssuedDuringPeriodSharesIssuedForServices_2_Q2_shares":35954.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":25894690.0,"CashCashEquivalentsAndShortTermInvestments_0_Q2_USD":134087800.0,"OtherPrepaidExpenseCurrent_0_Q2_USD":45200.0,"AccruedLiabilitiesAndOtherLiabilities_0_Q2_USD":1360900.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":442506.0,"AccruedBonusesCurrentAndNoncurrent_0_Q2_USD":593400.0,"OtherAssetsNoncurrent_0_Q2_USD":25000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":13824258.0,"ContractualObligationDueInSecondYear_0_Q2_USD":null,"PreferredStockSharesOutstanding_0_Q2_shares":null,"ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0_Q2_shares":49196.0,"ShortTermInvestments_0_Q2_USD":120263581.0,"InvestmentIncomeInterestAndDividend_2_Q2_USD":811657.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther_2_Q2_shares":1018367.0,"IncreaseDecreaseInLeasingReceivables_2_Q2_USD":-35782.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":13800.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-8378419.0,"ProceedsFromWarrantExercises_2_Q2_USD":5619276.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2_Q2_USD":0.0,"LiabilitiesCurrent_0_Q2_USD":2326102.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":-22454261.0,"PaymentsForProceedsFromInvestments_2_Q2_USD":62364176.0,"AccountsPayableCurrent_0_Q2_USD":965169.0,"NonoperatingIncomeExpense_2_Q2_USD":939883.0,"NonoperatingIncomeExpense_1_Q2_USD":1638761.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":530643.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":65900.0,"AdditionalPaidInCapital_0_Q2_USD":273868163.0,"PrepaidInsurance_0_Q2_USD":20600.0,"SharesIssued_0_Q2_shares":427700.0,"PreferredStockSharesIssued_0_Q2_shares":null,"PropertyPlantAndEquipmentNet_0_Q2_USD":2935.0,"NetIncomeLoss_2_Q2_USD":-21791757.0,"CommonStockSharesOutstanding_0_Q2_shares":15851853.0,"ContractualObligationDueAfterFifthYear_0_Q2_USD":null,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_1_Q2_USD":7302513.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-141650666.0,"NotesPayable_0_Q2_USD":0.0,"CommonStockSharesAuthorized_0_Q2_shares":50000000.0,"OperatingIncomeLoss_2_Q2_USD":-22731640.0,"OperatingIncomeLoss_1_Q2_USD":-12757202.0,"SettlementLiabilitiesCurrent_0_Q2_USD":null,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":134559451.0,"ProceedsFromRepaymentsOfNotesPayable_2_Q2_USD":-110247.0,"PreferredStockSharesAuthorized_0_Q2_shares":200000000.0,"InvestmentIncomeInterestAndDividend_1_Q2_USD":404004.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":12341900.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q2_USD":103000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":16700.0,"OperatingExpenses_2_Q2_USD":22731640.0,"OperatingExpenses_1_Q2_USD":12757202.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.45,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.73,"StockholdersEquity_0_Q2_USD":132233349.0,"LeaseIncentiveReceivableNoncurrent_0_Q2_USD":126935.0,"LeaseIncentiveReceivableCurrent_0_Q2_USD":76208.0,"ProceedsFromIssuanceOfWarrants_2_Q2_USD":19855018.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":139100.0,"Ticker":"RLMD","CIK":"1553643","name":"RELMADA THERAPEUTICS, INC.","OfficialName":"Relmada Therapeutics Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"772606380.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200812"}]